Amgen - Erythropoietin (EPO) - Patent Portfolio ReportSunlight Research, LLCApril 1, 2010 20 Pages - SKU: SLR2755642 |
Patents that cover FDA approved pharmaceutical drug products are listed in the FDA’s Orange Book. Unlike pharmaceuticals, FDA approved biological drug products and the patents that protect them are not presently included in the Orange Book. However, biologicals are subject to FDA mandated labeling requirements that are similar to those required for pharmaceuticals. Following extensive searching of the U.S. patent database, relevant erythropoietin patents were identified. Product information on Epogen® was obtained from the FDA-approved product label and other reliable sources, such as case law, to determine which patents cover the currently marketed product. This report provides an Orange Book-like list of U.S. patents that cover Amgen’s product, Epogen®. But this report goes beyond a mere listing of relevant patents. In addition, this report provides a detailed analysis of these patents to identify the commercially relevant claims and claim limitations. This report is designed for quick and easy understanding of the technology for all professionals. This report can be used by business, technical and legal professionals to visualize erythropoietin technologies covered by Amgen’s patent portfolio and their commercial applications. Patent Portfolio Reports are an essential part of product development and infringement analysis to assist with design-around technologies and to identify new technology areas for development. Biological drug products such as vaccines, gene therapies, recombinant therapeutic proteins and blood products represent expanding and valuable areas of technology. With increasing focus on follow-on biologicals, an understanding of the patent landscape and patent protection of current and new biologicals will be critical to branded and generic drug companies alike.
|
